Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Research tools

JZL184

The reference MAGL inhibitor. In mice it raises brain 2-AG eight-fold without changing anandamide.

Unscheduled
Level of detail

C₂₇H₂₄N₂O₉

CAS 1101854-58-3

Family
ECS pharmacological toolEnzyme inhibitor
Origin
Pharmaceutical research (Cravatt)
First described
2009
Molar mass
520.50 g/mol

Updated on

In plain terms

JZL184 stops an enzyme (MAGL) from destroying 2-AG, a cannabinoid made by the body: its level then rises in the mouse brain. It is a laboratory tool, not intended for humans.

Receptors and activity

Target network

MAGLInhibitorIC50 = 8 nM · mousebrain membranes; 6 nM on recombinant human MAGL (COS-7 cells)
  • Blocks or inhibits

The lower the cited value, the closer the target sits to JZL184: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of JZL184.

Brain, side view
Body, front view
Blood

MAGLMAGL found in 5 regions of the body

  1. CortexdenseHighest PET signal in the cerebral cortex1
  2. Basal gangliapresentModerate levels in the putamen1
  3. HippocampuspresentAxon terminals in the hippocampus2
  4. Adipose tissuepresentPresent in subcutaneous adipose tissue3
  5. Immune cellspresentRNA enhanced in blood monocytes4

Map sources

  1. Takahata K et al. First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with (18)F-T-401. Eur J Nucl Med Mol Imaging, 2022 (new tab)
  2. Ludányi A et al. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience, 2011 (new tab)
  3. Spoto B et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie, 2006 (new tab)
  4. Human Protein Atlas. MGLL expression summary (new tab)

Cited values

  1. MAGLInhibitorIC50 = 8 nM · mouse68 out of 100

    Long et al., Nat Chem Biol 2009 (new tab) · brain membranes; 6 nM on recombinant human MAGL (COS-7 cells)

  2. FAAHInhibitorIC50 = 4 µM · mouse23 out of 100

    Long et al., Nat Chem Biol 2009 (new tab) · brain membranes; weak inhibition (selectivity for MAGL)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of JZL184, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

JZL184 is a MAGL inhibitor, a piperidine carbamate described by Long et al. (Nat Chem Biol 2009, PMID 19029917) at the Scripps Research Institute. Given to mice, it raises brain 2-AG eight-fold without changing anandamide and produces CB1-dependent effects (analgesia, hypothermia, hypomotility). It inhibits MAGL irreversibly by carbamoylating its nucleophilic serine (Long, Nomura and Cravatt, Chem Biol 2009, PMID 19635411). Repeated MAGL blockade led in mice to tolerance, desensitisation of brain CB1 receptors and physical dependence (Schlosburg et al., Nat Neurosci 2010, PMID 20729846), which limits its use in prolonged administration. It is a laboratory tool with no use in humans.

Key sources.

Origin

Research tool

An irreversible inhibitor of MAGL; a synthetic piperidine carbamate that carbamoylates the enzyme's nucleophilic serine.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

JZL184 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Long et al., Nat Chem Biol 2009: JZL184, selective MAGL inhibitor (new tab)PMID 19029917
  2. Long, Nomura & Cravatt, Chem Biol 2009: mechanism (carbamoylation of the nucleophilic serine) and tissue selectivity (new tab)PMID 19635411
  3. Schlosburg et al., Nat Neurosci 2010: chronic MAGL blockade and functional antagonism of the endocannabinoid system (new tab)PMID 20729846

Identifiers

Names

IUPAC name
(4-nitrophenyl) 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate
Other names
JZL-184

Identifiers

Formula
C₂₇H₂₄N₂O₉
CAS
1101854-58-3
PubChem CID
25021165(new tab)
InChIKey
SEGYOKHGGFKMCX-UHFFFAOYSA-N
SMILES
C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC6=CC=C(C=C6)[N+](=O)[O-]

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.